Fort Collins, CO, United States of America

Eileen M Jarr


Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 365(Granted Patents)


Company Filing History:


Years Active: 2000-2003

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eileen M Jarr: Innovator in Controlled Release Drug Delivery

Introduction

Eileen M Jarr is a prominent inventor based in Fort Collins, CO (US). She has made significant contributions to the field of controlled release drug delivery systems. With a total of 2 patents, her work focuses on improving the efficacy and safety of drug delivery methods.

Latest Patents

Eileen's latest patents include innovative compositions for controlled release liquid delivery. The first patent, titled "Controlled release liquid delivery compositions with low initial drug burst," describes a polymeric composition that incorporates a base polymer or copolymer, an organic solvent, a polymeric controlled release additive, and a biologically active agent. This invention aims to reduce the initial burst of the biologically active agent released from the polymeric composition as it solidifies into a solid implant. The controlled release additive is preferably a poly(lactide-co-glycolide)/polyethylene glycol block copolymer. The second patent shares a similar focus, emphasizing the same components and benefits in controlled release drug delivery.

Career Highlights

Eileen M Jarr is currently associated with Atrix Laboratories, Inc., where she continues to advance her research in drug delivery systems. Her work has been instrumental in developing new technologies that enhance the effectiveness of medications.

Collaborations

Eileen has collaborated with notable colleagues, including Bhagya L Chandrashekar and Mingxing Zhou. These partnerships have contributed to the innovative advancements in her field.

Conclusion

Eileen M Jarr's contributions to controlled release drug delivery systems highlight her role as a leading inventor in the pharmaceutical industry. Her patents reflect a commitment to improving patient outcomes through innovative drug delivery technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…